<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Support Care Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Support Care Cancer</journal-id><journal-title-group><journal-title>Supportive Care in Cancer</journal-title></journal-title-group><issn pub-type="ppub">0941-4355</issn><issn pub-type="epub">1433-7339</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394376</article-id><article-id pub-id-type="pmc">PMC12092496</article-id>
<article-id pub-id-type="publisher-id">9521</article-id><article-id pub-id-type="doi">10.1007/s00520-025-09521-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Quality of life and supportive care needs in prostate cancer: the impact of treatment received and care service utilization among M&#x00101;ori and non-M&#x00101;ori patients in New Zealand</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baxter</surname><given-names>G. David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lizhou</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoeta</surname><given-names>Tobias</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wibowo</surname><given-names>Erik</given-names></name><address><email>erik.wibowo@sydney.edu.au</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01jmxt844</institution-id><institution-id institution-id-type="GRID">grid.29980.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7830</institution-id><institution>Centre for Men&#x02019;s Health NZ, Centre for Health, Activity and Rehabilitation Research, School of Physiotherapy, </institution><institution>University of Otago, </institution></institution-wrap>PO Box 56, Dunedin, 9054 New Zealand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dbr7087</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution>Present Address: Exercise Oncology Lab, Faculty of Kinesiology and Physical Education, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01jmxt844</institution-id><institution-id institution-id-type="GRID">grid.29980.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7830</institution-id><institution>Centre for Men&#x02019;s Health NZ, Department of Anatomy, </institution><institution>University of Otago, </institution></institution-wrap>PO Box 56, Dunedin, 9054 New Zealand </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Present Address: School of Medical Sciences, Faculty of Medicine and Health, </institution><institution>University of Sydney, </institution></institution-wrap>Camperdown, Australia </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>33</volume><issue>6</issue><elocation-id>483</elocation-id><history><date date-type="received"><day>25</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par14">Prostate cancer treatment can lead to significant long-term side effects that impact patients&#x02019; quality of life and supportive care needs (SCN). This study explores the associations between quality of life (QoL) and SCN among prostate cancer survivors, with a focus on the impact of treatment received, care service utilization, and the differences between M&#x00101;ori and non-M&#x00101;ori patients.</p></sec><sec><title>Methods</title><p id="Par15">Random stratified sampling data were collected from 1075 prostate cancer survivors who were diagnosed within the past 5&#x000a0;years. Hierarchical regression analyses examined the associations between QoL domains and SCN, adjusting for demographic, clinical, and treatment-related factors. LASSO (Least Absolute Shrinkage and Selection Operator) was used to select variables to test the interaction effects of different treatments.</p></sec><sec><title>Results</title><p id="Par16">Significant disparities were found between M&#x00101;ori and non-M&#x00101;ori patients in physical and mental health scores, care service utilization, and overall SCN. M&#x00101;ori men had lower scores in these areas. Most QoL domains were negatively associated with more SCN, particularly mental health and hormonal issues. Androgen deprivation therapy (ADT) exacerbates some negative effects of poor mental health and hormonal issues for non-M&#x00101;ori, while the use of care services and radical prostatectomy (RP) was associated with mitigating SCN for M&#x00101;ori patients.</p></sec><sec><title>Conclusion</title><p id="Par17">This study highlights the complex interplay between QoL, SCN, and treatment modalities among prostate cancer survivors in New Zealand. The findings underscore the need for culturally tailored supportive care services to address the unique needs of M&#x00101;ori patients.
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00520-025-09521-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Care service utilization</kwd><kwd>M&#x00101;ori and non-M&#x00101;ori patients</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Otago</institution></funding-source></award-group><open-access><p>Open access funding provided by The University of Otago.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par18">In New Zealand (NZ), prostate cancer is the most commonly diagnosed cancer among men, with favorable 5- and 10-year survival rates are over 95% and 90%, respectively [<xref ref-type="bibr" rid="CR1">1</xref>]. The widespread use of prostate-specific antigen (PSA) testing has had a profound impact on prostate cancer incidence [<xref ref-type="bibr" rid="CR2">2</xref>]. Over the past two decades, the incidence has risen from 40 cases per 100,000 in the pre-PSA era to over 100 cases per 100,000, suggesting that up to 50% of cases may be over diagnosed [<xref ref-type="bibr" rid="CR2">2</xref>]. This places additional strain on healthcare resources by increasing the number of men requiring monitoring or treatments. Many prostate cancer survivors (PCS) suffer from long-term side effects from these treatments, such as urinary incontinence, erectile dysfunction, fatigue, depression and anxiety [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. These side effects extend far beyond the physical, deeply impacting their quality of life (QoL). Consequently, supportive care emerges as a pivotal element in enhancing QoL for PCS.
</p><p id="Par19">The relationship between QoL and supportive care needs (SCN) in PCS has significantly evolved as a crucial area of study over the years. Improving QoL and addressing unmet needs go beyond known physical, psychological and informational aspects. The variations in treatments and outcomes also affect the post-treatment lives of PCS. Research has demonstrated that while medical treatments for prostate cancer can extend life expectancy, they often come with side effects that can severely impact the QoL of survivors [<xref ref-type="bibr" rid="CR5">5</xref>]. Patients who received external radiation and brachytherapy tend to have a worse bowel function, but better or equivalent urinary and sexual function compared with those who had prostatectomy [<xref ref-type="bibr" rid="CR6">6</xref>]. A comprehensive systematic review highlighted that a significant proportion of PCS continues to experience substantial unmet SCN after treatments, particularly in areas concerning sexual health, mental wellbeing, and coping strategies [<xref ref-type="bibr" rid="CR7">7</xref>]. A study across seven European countries also showed that factors such as the stage of cancer at diagnosis, treatment modality received (e.g., surgery, radiotherapy, hormonal therapy), and socio-demographic characteristics (age, income level, and educational background) play a pivotal role in shaping these needs [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par20">In NZ, the utilization of supportive care services is fragmented and inequitable. The supportive care services for PCS in NZ are predominantly provided in urology and oncology services at Te Whatu Ora&#x02014;Health NZ. Although the government raised the investment by committing approximately $4.2 million annually to the Cancer Psychological and Social Support Initiative [<xref ref-type="bibr" rid="CR9">9</xref>] and there are community support organizations consistently providing care services including peer support groups, exercise programs, education seminars/webinars, and online support consultations. PCS in NZ still frequently report unmet needs after completing active treatments, which are not adequately addressed by the current supportive care services [<xref ref-type="bibr" rid="CR10">10</xref>]. M&#x00101;ori, the Indigenous people of Aotearoa NZ, experience higher SCN yet utilize fewer services due to structural inequities and unique cultural barriers [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Additionally, many P&#x00101;keh&#x00101; (NZ European) men receive treatment in the private sector rather than through Te Whatu Ora&#x02014;Health NZ [<xref ref-type="bibr" rid="CR3">3</xref>]. While private care often provides advantages such as shorter wait times and greater flexibility in choosing treatment options, it may limit access to integrated supportive care services, which are more systematically embedded within the public healthcare system. In contrast, M&#x00101;ori men face distinct challenges, including barriers to accessing follow-up care and limited knowledge about prostate cancer symptoms [<xref ref-type="bibr" rid="CR11">11</xref>]. These factors are compounded by cultural differences in healthcare preferences, with M&#x00101;ori patients often requiring tailored supportive care services that address their unique cultural and social needs [<xref ref-type="bibr" rid="CR12">12</xref>]. These disparities emphasize the need for culturally tailored interventions to meet diverse patient needs and improve QoL to ensure equitable care for all men with prostate cancer in NZ.</p><p id="Par21">Therefore, the primary aim of this study is to explore the associations between QoL and SCN among PCS and assess how different treatment modalities and supportive care service utilization moderate these relationships. This allows us to dissect the nuances of treatment effects, potentially identifying which modalities are associated with better or worse QoL and higher or lower needs for supportive care. Understanding these relationships will inform targeted supportive care strategies, ultimately enhancing QoL and addressing healthcare disparities for all PCS in NZ.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Participants and procedure</title><p id="Par22">This study was conducted in NZ in October 2023. Data for 17,886 men diagnosed with prostate cancer within the past 5 years were obtained from the electronic database of the Cancer Registry, Ministry of Health, and cross-verified with the Prostate Cancer Outcome Registry New Zealand. Only non-metastatic PCS with Gleason Scores &#x02264;&#x02009;7 and TNM staging &#x02264;&#x02009;2 was included, as metastatic PCS often have distinct clinical trajectories and SCN [<xref ref-type="bibr" rid="CR13">13</xref>]. Participants were randomly stratified into four groups (<italic>N</italic>&#x02009;= 1000 each) by diagnosis dates (within 1 year, 1 to 3 years, 3 to 5 years) and ethnicity, with an additional group exclusively composing of M&#x00101;ori men equally distributed across these timeframes. The total sample size for the study was 4000 participants.</p><p id="Par23">Participant engagement (<xref rid="MOESM1" ref-type="media">Appendix A</xref>) included consultations with a M&#x00101;ori co-investigator and prostate cancer supportive care providers, and a pilot study was conducted using face-to-face and online surveys. A study webpage was created providing detailed information, including informed consent and confidentiality assurances [<xref ref-type="bibr" rid="CR14">14</xref>]. Custom postcards (<xref rid="MOESM2" ref-type="media">Appendix B</xref>) with links and QR codes were distributed, enabling online survey completion via REDCap or requests for paper-based questionnaires. This study was approved by the New Zealand Health and Disability Ethics Committee (HDEC) (ref_2022 EXP 11640) and conducted in accordance with the Declaration of Helsinki. M&#x00101;ori Research Consultation was made through the Ng&#x00101;i Tahu Research Consultation Committee, University of Otago (ref: 5767_21979).</p></sec><sec id="Sec4"><title>Survey measurements</title><p id="Par24">The development of the survey instruments and measurement approach has been previously reported [<xref ref-type="bibr" rid="CR4">4</xref>]. Table <xref rid="Tab1" ref-type="table">1</xref> provides an overview of the key instruments and measures utilized in this study. SCN were assessed using the Supportive Care Needs Survey Short Form (SCNS-34SF [<xref ref-type="bibr" rid="CR15">15</xref>]. For M&#x00101;ori participants, a culturally adapted version was developed based on the Supportive Care Needs Assessment Tool for Indigenous People (SCNAT-IP). The SCNAT-IP was originally developed for Indigenous Australian populations, and we adapted it for M&#x00101;ori participants in consultation with a M&#x00101;ori co-investigator to ensure cultural relevance [<xref ref-type="bibr" rid="CR16">16</xref>]. QoL was evaluated through Expanded Prostate Cancer Index Composite Short Form EPIC-26, which assesses prostate cancer-specific symptoms, and Medical Outcomes Study SF-12v2 (SF-12v2), which measures physical and mental health domains [<xref ref-type="bibr" rid="CR17">17</xref>]. The Care Service Utilization Scale was developed drawing on three principal sources: [1] the methodological framework established by Cockle-Hearne et al. [<xref ref-type="bibr" rid="CR8">8</xref>], which utilized expert input from clinical specialists, [2] evidence synthesized from a systematic review by King et al. [<xref ref-type="bibr" rid="CR18">18</xref>], and (3) consultations with key representatives from the Prostate Cancer Foundation NZ and Cancer Society NZ [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] (<xref rid="MOESM1" ref-type="media">Appendix A</xref>). Additionally, socio-demographic and medical data were collected to account for potential confounding factors in the analysis.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of measurements used in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Domain</th><th align="left">Instrument/source</th><th align="left">Description</th><th align="left">Scoring</th></tr></thead><tbody><tr><td align="left">Supportive care needs</td><td align="left">Supportive Care Needs Survey Short Form (SCNS-34SF)</td><td align="left">Assesses 34 supportive care needs across multiple domains. A M&#x00101;ori-adapted version incorporating cultural elements was used for M&#x00101;ori participants</td><td align="left">Standardized score (0&#x02013;100), higher scores indicate greater needs</td></tr><tr><td align="left">QoL and treatment</td><td align="left">Expanded Prostate Cancer Index Composite Short Form (EPIC-26) and SF-12v2</td><td align="left">EPIC-26: Assesses urinary, bowel, sexual, and hormonal symptoms; SF-12v2: Assesses physical and mental health</td><td align="left">Standardized score (0&#x02013;100), higher scores indicate better QoL</td></tr><tr><td align="left">Care service utilization</td><td align="left">Self-developed scale based on existing frameworks and stakeholder input</td><td align="left">Measures advice and support received from clinical professionals, NGOs, and other sources (19 items)</td><td align="left">Sum of total scores (0&#x02013;100), higher scores indicate greater utilization of services</td></tr><tr><td align="left">Control variables</td><td align="left">Socio-demographic and medical data</td><td align="left">Includes relationship status, education, income, employment, smoking, and medical conditions</td><td align="left">Categorical variables; comparisons made with a reference category</td></tr></tbody></table><table-wrap-foot><p>Inter-scale correlation between EPIC26 and SF-12 has indicated that efficient QOL assessment can be achieved by co-administering EPIC26 with SF-12</p><p>The Cronbach&#x02019;s alpha for SCNAT-IP and supportive care utilization scale was 0.98 and 0.83 respectively, indicating a high level of internal consistency and suggesting that the items reliably measure a cohesive underlying construct</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Data analysis</title><p id="Par25">The analysis was conducted using Stata version 17.0. Observations with over 80% missingness on any scale or an entirely missing instrument were excluded. Mean imputation was used after observing data patterns as missing completely at random. Descriptive statistics were computed to describe the participants&#x02019; socio-demographic characteristics, QoL and SCN. The relationship between QoL and SCN was analyzed through ordinary least squares (OLS) regression. Multivariate models were employed, adjusting for different control variables to assess their impact. The basic model explored the direct association between QoL and SCN using a single regression model with all QoL domains included. The adjusted model incorporated control variables, while the interaction model included treatment and service utilization variables based on the adjusted model. Due to the high number of interaction terms tested, the Least Absolute Shrinkage and Selection Operator (LASSO) linear regressions were employed for the interaction model to handle the potential multicollinearity and to perform variable selection. Similar hierarchical regression models were used for M&#x00101;ori participants using the sum score of SCNAT-IP M&#x00101;ori version as the outcome variable. Statistical significance was determined at a <italic>p</italic>-value of less than 0.05. Beta (<italic>&#x003b2;</italic>) coefficients and 95% confidence intervals (CIs) were reported for each model.</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par26">Data was based on 1075 complete questionnaires (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Participants&#x02019; demographics are in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, with NZ European men making up 74.60% and M&#x00101;ori men 16.19% due to oversampling. The average age of participants was 67.21 &#x000b1;&#x02009;15.62 years, with a similar age between the two ethnic groups. Most participants were married (71.04%) and lived with spouses (77.11%). M&#x00101;ori men were more likely to be widowed or divorced (38.04% vs. 14.03%). The retirement rate of 67.07% aligned with the age distribution of the cohort. Educationally, 48.70% had a high school diploma and 42.50% had a university education, with 47.13% of non-M&#x00101;ori participants reporting university or postgraduate education compared to 16.85% of M&#x00101;ori men. Economically, 45.27% of participants reported a household income between $30 k and $100 k, with comparable rates among M&#x00101;ori (42.39%) and non-M&#x00101;ori (46.07%). However, non-M&#x00101;ori participants were more likely to report household incomes exceeding $100 k (28.14%) compared to M&#x00101;ori participants (14.13%). Smoking prevalence was 8.73%, with significantly higher rates among M&#x00101;ori men (34.79%) compared to non-M&#x00101;ori men (3.52%). Approximately 48.83% reported no chronic medical conditions. Common health issues included diabetes (13.77%), heart-related ailments (13.76%), circulation problems (14.51%), asthma or emphysema (15.81%), and stomach ulcers (10.42%).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of patient selection for the data analyses</p></caption><graphic xlink:href="520_2025_9521_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>&#x000a0;Sociodemographic characteristics of study participants stratified by ethnicity (M&#x00101;ori vs non-M&#x00101;ori)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (%) (<italic>N</italic>=1075)</th><th align="left">M&#x00101;ori men (%) (<italic>N</italic>&#x02009;= 184)</th><th align="left">Non-M&#x00101;ori (%) (<italic>N</italic>&#x02009;= 891)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">67.21 &#x000b1;&#x02009;15.62</td><td align="left">66.54 &#x000b1;&#x02009;13.81</td><td align="left">67.49 &#x000b1;&#x02009;16.66</td></tr><tr><td align="left" colspan="4">Ethnicities</td></tr><tr><td align="left">&#x000a0; NZ European</td><td align="left">802 (74.60)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; M&#x00101;ori</td><td align="left">174 (16.19)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Cook Islands M&#x00101;ori</td><td align="left">10 (0.93)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Samoan</td><td align="left">9 (0.84)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Chinese</td><td align="left">8 (0.74)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Indian</td><td align="left">16 (1.49)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Niuean</td><td align="left">7 (0.65)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0; Others</td><td align="left">49 (4.56)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="4">Relationship</td></tr><tr><td align="left">&#x000a0; Living with spouse</td><td align="left">829 (77.11)</td><td align="left">95 (51.63)</td><td align="left">734 (82.45)</td></tr><tr><td align="left">&#x000a0; In a relationship, but not living together</td><td align="left">54 (5.02)</td><td align="left">16 (8.70)</td><td align="left">38 (4.24)</td></tr><tr><td align="left">&#x000a0; Not in a relationship</td><td align="left">192 (17.87)</td><td align="left">73 (39.67)</td><td align="left">119 (13.32)</td></tr><tr><td align="left" colspan="4">Education</td></tr><tr><td align="left">&#x000a0; Below high school level</td><td align="left">68 (6.30)</td><td align="left">33 (17.93)</td><td align="left">35(3.92)</td></tr><tr><td align="left">&#x000a0; High school level</td><td align="left">524 (48.70)</td><td align="left">109 (59.24)</td><td align="left">415 (46.54)</td></tr><tr><td align="left">&#x000a0; University level</td><td align="left">274 (25.43)</td><td align="left">21 (11.41)</td><td align="left">253 (28.37)</td></tr><tr><td align="left">&#x000a0; Postgraduate level</td><td align="left">183 (17.07)</td><td align="left">14 (7.61)</td><td align="left">169 (18.95)</td></tr><tr><td align="left">&#x000a0; Prefer not to say</td><td align="left">26 (2.50)</td><td align="left">7 (3.80)</td><td align="left">19 (2.22)</td></tr><tr><td align="left" colspan="4">Marital status</td></tr><tr><td align="left">&#x000a0; Married</td><td align="left">765 (71.04)</td><td align="left">83 (45.11)</td><td align="left">682 (73.95)</td></tr><tr><td align="left">&#x000a0; Never married</td><td align="left">57 (5.35)</td><td align="left">16 (8.70)</td><td align="left">41(2.52)</td></tr><tr><td align="left">&#x000a0; Separated</td><td align="left">33 (3.03)</td><td align="left">15 (8.15)</td><td align="left">18 (2.24)</td></tr><tr><td align="left">&#x000a0; Divorced</td><td align="left">135 (12.61)</td><td align="left">45 (24.46)</td><td align="left">90 (7.84)</td></tr><tr><td align="left">&#x000a0; Widower</td><td align="left">85 (7.97)</td><td align="left">25 (13.59)</td><td align="left">60 (6.44)</td></tr><tr><td align="left" colspan="4">Household income</td></tr><tr><td align="left">&#x000a0; Less than $10 k</td><td align="left">29 (2.72)</td><td align="left">24 (13.04)</td><td align="left">5 (0.52)</td></tr><tr><td align="left">&#x000a0; 10 k&#x02013;30 k</td><td align="left">176 (16.32)</td><td align="left">46 (25.00)</td><td align="left">130 (14.53)</td></tr><tr><td align="left">&#x000a0; 30 k&#x02013;100 k</td><td align="left">488 (45.27)</td><td align="left">78 (42.39)</td><td align="left">410 (46.07)</td></tr><tr><td align="left">&#x000a0; More than 100 k</td><td align="left">277 (25.90)</td><td align="left">26 (14.13)</td><td align="left">251 (28.14)</td></tr><tr><td align="left">&#x000a0; Prefer not to say</td><td align="left">105 (9.79)</td><td align="left">9 (4.89)</td><td align="left">96 (10.73)</td></tr><tr><td align="left" colspan="4">Employment</td></tr><tr><td align="left">&#x000a0; Full-time</td><td align="left">228 (21.22)</td><td align="left">30 (16.30)</td><td align="left">198 (22.22)</td></tr><tr><td align="left">&#x000a0; Part-time</td><td align="left">102 (9.51)</td><td align="left">17(9.24)</td><td align="left">85 (9.54)</td></tr><tr><td align="left">&#x000a0; Seeking opportunities</td><td align="left">12 (1.10)</td><td align="left">4 (2.17)</td><td align="left">8 (0.85)</td></tr><tr><td align="left">&#x000a0; Retired</td><td align="left">721 (67.07)</td><td align="left">128 (69.57)</td><td align="left">593 (65.55)</td></tr><tr><td align="left">&#x000a0; Prefer not to say</td><td align="left">12 (1.10)</td><td align="left">5 (2.72)</td><td align="left">7 (0.85)</td></tr><tr><td align="left" colspan="4">Smoke status</td></tr><tr><td align="left">&#x000a0; No</td><td align="left">980 (91.16)</td><td align="left">120 (65.21)</td><td align="left">860 (96.48)</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">95 (8.73)</td><td align="left">64 (34.79)</td><td align="left">31 (3.52)</td></tr><tr><td align="left" colspan="4">Treatment</td></tr><tr><td align="left">Expectant management watchful waiting</td><td align="left">201 (18.70)</td><td align="left">41 (23.56)</td><td align="left">160 (17.76)</td></tr><tr><td align="left">&#x000a0; Radical prostatectomy</td><td align="left">461 (42.88)</td><td align="left">72 (41.38)</td><td align="left">389 (43.17)</td></tr><tr><td align="left">&#x000a0; External Beam Radiation</td><td align="left">299 (27.81)</td><td align="left">50 (28.74)</td><td align="left">249 (27.64)</td></tr><tr><td align="left">&#x000a0; Radioactive Seed implantation</td><td align="left">72 (6.70)</td><td align="left">22 (12.64)</td><td align="left">50 (5.55)</td></tr><tr><td align="left">&#x000a0; Orchiectomy</td><td align="left">21 (1.95)</td><td align="left">3 (1.72)</td><td align="left">18 (2.00)</td></tr><tr><td align="left">&#x000a0; Androgen deprivation therapy</td><td align="left">184 (17.12)</td><td align="left">45 (25.86)</td><td align="left">139 (15.43)</td></tr><tr><td align="left">&#x000a0; Hormone pills</td><td align="left">57 (5.30)</td><td align="left">14 (8.05)</td><td align="left">43 (4.77)</td></tr><tr><td align="left">&#x000a0; Others</td><td align="left">85 (7.91)</td><td align="left">21 (11.41)</td><td align="left">64 (7.18)</td></tr><tr><td align="left" colspan="4">Medical conditions</td></tr><tr><td align="left">&#x000a0; No chronic medical</td><td align="left">525 (48.83)</td><td align="left">56 (30.43)</td><td align="left">469 (52.64)</td></tr><tr><td align="left">&#x000a0; Diabetes</td><td align="left">148 (13.77)</td><td align="left">67 (36.41)</td><td align="left">81 (9.09)</td></tr><tr><td align="left">&#x000a0; Heart attack, chest pain</td><td align="left">147 (13.76)</td><td align="left">27 (14.67)</td><td align="left">120 (13.47)</td></tr><tr><td align="left">&#x000a0; Stroke</td><td align="left">56 (5.21)</td><td align="left">26 (14.13)</td><td align="left">30 (3.37)</td></tr><tr><td align="left">&#x000a0; Amputation</td><td align="left">28 (2.60)</td><td align="left">9 (4.89)</td><td align="left">19 (2.13)</td></tr><tr><td align="left">&#x000a0; Circulation problems</td><td align="left">156 (14.51)</td><td align="left">49 (26.63)</td><td align="left">107 (12.01)</td></tr><tr><td align="left">&#x000a0; Asthma or emphysema</td><td align="left">170 (15.81)</td><td align="left">40 (21.74)</td><td align="left">130 (14.59)</td></tr><tr><td align="left">&#x000a0; Stomach ulcer, irritable bowel</td><td align="left">112 (10.42)</td><td align="left">30 (16.30)</td><td align="left">82 (9.20)</td></tr><tr><td align="left">&#x000a0; Kidney disease</td><td align="left">57 (5.30)</td><td align="left">16 (8.70)</td><td align="left">41 (4.60)</td></tr><tr><td align="left">&#x000a0; Major depression</td><td align="left">59 (5.49)</td><td align="left">22 (11.96)</td><td align="left">37 (4.15)</td></tr><tr><td align="left">&#x000a0; Seizures</td><td align="left">18 (1.67)</td><td align="left">2 (1.09)</td><td align="left">16 (1.80)</td></tr><tr><td align="left">&#x000a0; Alcoholism or alcohol problem</td><td align="left">57 (5.30)</td><td align="left">28 (15.22)</td><td align="left">29 (3.25)</td></tr><tr><td align="left">&#x000a0; Drug problems</td><td align="left">35 (3.26)</td><td align="left">18 (9.78)</td><td align="left">17 (1.91)</td></tr></tbody></table></table-wrap></p><p id="Par27">Table <xref rid="Tab3" ref-type="table">3</xref>&#x000a0;shows the disparities in QoL and SCN outcomes between M&#x00101;ori and non-M&#x00101;ori. Specifically, physical and mental health scores for M&#x00101;ori were significantly lower than those for non-M&#x00101;ori (physical health: <italic>d</italic>&#x02009;= &#x02212;&#x02009;0.32, <italic>p</italic>&#x02009;&#x0003c; 0.001; mental health: <italic>d</italic>&#x02009;= &#x02212;&#x02009;0.92, <italic>p</italic>&#x02009;&#x0003c; 0.001). EPIC-26 scores across domains such as urinary incontinence, bowel, and sexual functioning indicated greater adverse impacts on M&#x00101;ori (e.g., urinary incontinence: <italic>d</italic>&#x02009;= &#x02212;&#x02009;0.48, <italic>p</italic>&#x02009;&#x0003c; 0.001; bowel: <italic>d</italic>&#x02009;= &#x02212;&#x02009;0.82, <italic>p</italic>&#x02009;&#x0003c; 0.001). Furthermore, care service utilization scores also demonstrated a significantly lower care utilization among M&#x00101;ori (26.20) compared to non-M&#x00101;ori (41.84) (<italic>d</italic>&#x02009;= &#x02212;&#x02009;0.79, <italic>p</italic>&#x02009;&#x0003c; 0.001). Correspondingly, M&#x00101;ori men had significantly higher overall standardized SCN scores (<italic>d</italic>&#x02009;= 0.97, <italic>p</italic>&#x02009;&#x0003c; 0.001) compared to non-M&#x00101;ori.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of scores for QoL, service utilization, and supportive care needs between M&#x00101;ori and non-M&#x00101;ori participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total (<italic>N</italic>&#x02009;= 1075)</th><th align="left">M&#x00101;ori</th><th align="left">Non-M&#x00101;ori</th><th align="left"><italic>d</italic></th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="6">SF12v2</td></tr><tr><td align="left">Physical health</td><td align="left">44.39 (7.27)</td><td align="left">42.47 (7.20)</td><td align="left">44.78 (7.23)</td><td align="left">&#x02009;&#x02212; 0.32</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Mental health</td><td align="left">52.08 (9.84)</td><td align="left">44.96 (11.48)</td><td align="left">53.54 (8.80)</td><td align="left">&#x02009;&#x02212; 0.92</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left" colspan="6">EPIC-26</td></tr><tr><td align="left">Urinary incontinence</td><td align="left">76.16 (20.89)</td><td align="left">67.87 (20.80)</td><td align="left">77.76 (20.53)</td><td align="left">&#x02009;&#x02212; 0.48</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Urinary obstructive</td><td align="left">83.57 (16.78)</td><td align="left">69.43 (23.79)</td><td align="left">86.30 (13.46)</td><td align="left">&#x02009;&#x02212; 1.08</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Bowel</td><td align="left">86.75 (17.01)</td><td align="left">75.58 (23.98)</td><td align="left">88.90 (14.35)</td><td align="left">&#x02009;&#x02212; 0.82</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Sexual</td><td align="left">30.43 (24.57)</td><td align="left">21.77 (21.59)</td><td align="left">32.10 (24.77)</td><td align="left">&#x02009;&#x02212; 0.43</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Hormonal</td><td align="left">83.95 (16.35)</td><td align="left">73.43 (22.35)</td><td align="left">85.99 (14.05)</td><td align="left">&#x02009;&#x02212; 0.80</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Care service utilizations</td><td align="left">39.05 (20.71)</td><td align="left">26.20 (21.81)</td><td align="left">41.84 (19.38)</td><td align="left">&#x02009;&#x02212; 0.79</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left" colspan="6">SCNS</td></tr><tr><td align="left">Overall needs</td><td align="left"/><td align="left">41.89 (31.44)</td><td align="left">21.22 (33.01)</td><td align="left">0.97</td><td align="left">&#x02009;&#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>Comparison of independent and dependent variables between M&#x00101;ori men and non-M&#x00101;ori men</p><p><sup>&#x000c6;</sup>Two-sample <italic>T</italic>-tests: mean (standard deviation, SD) was reported</p><p>All data as standardized from 0 to 100</p></table-wrap-foot></table-wrap></p><p id="Par28">Tables <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref> present the regression analyses for non-M&#x00101;ori and M&#x00101;ori participants, respectively. For non-M&#x00101;ori patients, poorer mental health was the strongest predictor of higher SCN in the basic model (<italic>&#x003b2;</italic>&#x02009;= &#x02013;8.50, <italic>p</italic>&#x02009;&#x0003c; 0.001), and several symptom-specific QoL issues (e.g., urinary and bowel problems) were also associated with greater needs in unadjusted analyses. After adjusting for covariates, mental health remained a dominant predictor of SCN (<italic>&#x003b2;</italic>&#x02009;= &#x02013;5.09, <italic>p</italic>&#x02009;= 0.003), and physical health became a significant predictor as well (<italic>&#x003b2;</italic>&#x02009;= &#x02013;4.23, <italic>p</italic>&#x02009;= 0.014). In the interaction model, ADT use further exacerbated the impact of poor mental health on SCN (&#x003b2;_interaction =&#x02009;&#x02013;4.27, <italic>p</italic>&#x02009;= 0.003). Additionally, PCS with bowel dysfunction had especially high SCN if they were on ADT (&#x003b2;_interaction =&#x02009;&#x02013;2.80, <italic>p</italic>&#x02009;= 0.047) or managed with watchful waiting (&#x003b2;_interaction =&#x02009;&#x02013;4.04, <italic>p</italic>&#x02009;= 0.008).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Hierarchical regression models for QoL and supportive care needs (non-M&#x00101;ori)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Overall supportive care needs (non-M&#x00101;ori)</th><th align="left" colspan="4">Basic model</th><th align="left" colspan="4">Adjusted model</th><th align="left" colspan="4">Interaction model</th></tr><tr><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left" colspan="2">95% CI</th><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left" colspan="2">95% CI</th><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left" colspan="2">95% CI</th></tr></thead><tbody><tr><td align="left">Physical health</td><td align="left">0.31</td><td align="left">0.483</td><td align="left">&#x02009;&#x02212; 0.56</td><td align="left">1.17</td><td align="left">&#x02009;&#x02212; 0.11</td><td align="left">0.831</td><td align="left">&#x02009;&#x02212; 1.10</td><td align="left">0.13</td><td align="left">&#x02009;&#x02212; 4.16</td><td align="left">0.022</td><td align="left">&#x02009;&#x02212; 7.71</td><td align="left">&#x02009;&#x02212; 0.62</td></tr><tr><td align="left">Mental health</td><td align="left">&#x02009;&#x02212; 3.95</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 4.99</td><td align="left">&#x02009;&#x02212; 2.91</td><td align="left">&#x02009;&#x02212; 3.49</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 4.73</td><td align="left">&#x02009;&#x02212; 0.32</td><td align="left">&#x02009;&#x02212; 2.47</td><td align="left">0.098</td><td align="left">&#x02009;&#x02212; 5.40</td><td align="left">0.46</td></tr><tr><td align="left">Urinary incontinence</td><td align="left">&#x02009;&#x02212; 0.83</td><td align="left">0.069</td><td align="left">&#x02009;&#x02212; 1.72</td><td align="left">0.07</td><td align="left">&#x02009;&#x02212; 0.90</td><td align="left">0.085</td><td align="left">&#x02009;&#x02212; 1.93</td><td align="left">0.01</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Urinary obstructive</td><td align="left">&#x02009;&#x02212; 0.77</td><td align="left">0.179</td><td align="left">&#x02009;&#x02212; 1.89</td><td align="left">0.35</td><td align="left">&#x02009;&#x02212; 2.22</td><td align="left">0.002</td><td align="left">&#x02009;&#x02212; 3.62</td><td align="left">0.01</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Bowel</td><td align="left">&#x02009;&#x02212; 2.26</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 3.29</td><td align="left">&#x02009;&#x02212; 1.23</td><td align="left">&#x02009;&#x02212; 2.37</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 3.58</td><td align="left">&#x02009;&#x02212; 0.06</td><td align="left">&#x02009;&#x02212; 3.78</td><td align="left">0.009</td><td align="left">&#x02009;&#x02212; 6.62</td><td align="left">&#x02009;&#x02212; 0.93</td></tr><tr><td align="left">Sexual</td><td align="left">&#x02009;&#x02212; 1.38</td><td align="left">0.002</td><td align="left">&#x02009;&#x02212; 2.23</td><td align="left">&#x02009;&#x02212; 0.52</td><td align="left">&#x02009;&#x02212; 1.36</td><td align="left">0.005</td><td align="left">&#x02009;&#x02212; 2.31</td><td align="left">&#x02009;&#x02212; 0.02</td><td align="left">&#x02009;&#x02212; 1.95</td><td align="left">0.077</td><td align="left">&#x02009;&#x02212; 4.12</td><td align="left">0.21</td></tr><tr><td align="left">Hormonal</td><td align="left">&#x02009;&#x02212; 3.86</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 4.96</td><td align="left">&#x02009;&#x02212; 2.76</td><td align="left">&#x02009;&#x02212; 5.41</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 6.71</td><td align="left">&#x02009;&#x02212; 0.17</td><td align="left">&#x02009;&#x02212; 5.81</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 7.26</td><td align="left">&#x02009;&#x02212; 4.36</td></tr><tr><td align="left" colspan="13">Relationship (vs living with spouse)</td></tr><tr><td align="left">In a relationship, not living together</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.27</td><td align="left">0.924</td><td align="left">&#x02009;&#x02212; 5.73</td><td align="left">5.11</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Not in a relationship</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.08</td><td align="left">0.621</td><td align="left">&#x02009;&#x02212; 3.19</td><td align="left">8.71</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Marital status (vs never married)</td></tr><tr><td align="left">Married</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.75</td><td align="left">0.275</td><td align="left">&#x02009;&#x02212; 2.19</td><td align="left">9.72</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Separated</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.01</td><td align="left">0.998</td><td align="left">&#x02009;&#x02212; 7.27</td><td align="left">2.77</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Divorced</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.58</td><td align="left">0.558</td><td align="left">&#x02009;&#x02212; 3.72</td><td align="left">10.89</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Widower</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.29</td><td align="left">0.922</td><td align="left">&#x02009;&#x02212; 6.05</td><td align="left">1.61</td><td align="left">&#x02009;&#x02212; 3.07</td><td align="left">0.072</td><td align="left">&#x02009;&#x02212; 6.41</td><td align="left">0.27</td></tr><tr><td align="left" colspan="13">Employment (vs full-time)</td></tr><tr><td align="left">Part-time</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 2.70</td><td align="left">0.128</td><td align="left">&#x02009;&#x02212; 6.19</td><td align="left">1.41</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Seeking opportunities</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.43</td><td align="left">0.497</td><td align="left">&#x02009;&#x02212; 6.46</td><td align="left">9.42</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Retired</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.70</td><td align="left">0.597</td><td align="left">&#x02009;&#x02212; 3.31</td><td align="left">1.93</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Prefer not to say</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">13.11</td><td align="left">0.118</td><td align="left">&#x02009;&#x02212; 3.32</td><td align="left">23.19</td><td align="left">6.01</td><td align="left">0.208</td><td align="left">&#x02009;&#x02212; 3.34</td><td align="left">15.36</td></tr><tr><td align="left" colspan="13">Smoke status (vs non-smoker)</td></tr><tr><td align="left">Smoke</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 1.25</td><td align="left">0.609</td><td align="left">&#x02009;&#x02212; 6.03</td><td align="left">3.53</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Education (vs below high school level)</td></tr><tr><td align="left">High school level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 5.51</td><td align="left">0.036</td><td align="left">&#x02009;&#x02212; 10.65</td><td align="left">&#x02009;&#x02212; 0.38</td><td align="left">1.25</td><td align="left">0.579</td><td align="left">&#x02009;&#x02212; 3.19</td><td align="left">5.70</td></tr><tr><td align="left">University level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 5.05</td><td align="left">0.062</td><td align="left">&#x02009;&#x02212; 10.36</td><td align="left">0.26</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Postgraduate level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 6.19</td><td align="left">0.029</td><td align="left">&#x02009;&#x02212; 11.75</td><td align="left">&#x02009;&#x02212; 0.62</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Prefer not to say</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 5.17</td><td align="left">0.312</td><td align="left">&#x02009;&#x02212; 15.21</td><td align="left">4.87</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Household income (vs below 100 k)</td></tr><tr><td align="left">More than 100 k</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.40</td><td align="left">0.744</td><td align="left">&#x02009;&#x02212; 2.82</td><td align="left">2.02</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Medical conditions (vs no conditions)</td></tr><tr><td align="left">Diabetes</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 1.10</td><td align="left">0.481</td><td align="left">&#x02009;&#x02212; 4.15</td><td align="left">1.95</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Heart attack, chest pain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.83</td><td align="left">0.526</td><td align="left">&#x02009;&#x02212; 3.39</td><td align="left">1.73</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Stroke</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 3.12</td><td align="left">0.179</td><td align="left">&#x02009;&#x02212; 7.66</td><td align="left">1.43</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Amputation</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.55</td><td align="left">0.609</td><td align="left">&#x02009;&#x02212; 4.39</td><td align="left">7.48</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Circulation problems</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.04</td><td align="left">0.145</td><td align="left">&#x02009;&#x02212; 0.70</td><td align="left">4.79</td><td align="left">&#x02009;&#x02212; 2.00</td><td align="left">0.122</td><td align="left">&#x02009;&#x02212; 4.54</td><td align="left">0.53</td></tr><tr><td align="left">Asthma or emphysema</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.55</td><td align="left">0.217</td><td align="left">&#x02009;&#x02212; 0.91</td><td align="left">4.01</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Stomach ulcer, irritable bowel</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.21</td><td align="left">0.893</td><td align="left">&#x02009;&#x02212; 2.83</td><td align="left">3.24</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Kidney disease</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.39</td><td align="left">0.109</td><td align="left">&#x02009;&#x02212; 0.76</td><td align="left">7.53</td><td align="left">&#x02009;&#x02212; 2.89</td><td align="left">0.141</td><td align="left">&#x02009;&#x02212; 6.75</td><td align="left">0.96</td></tr><tr><td align="left">Major depression</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.43</td><td align="left">0.852</td><td align="left">&#x02009;&#x02212; 4.97</td><td align="left">4.10</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Seizures</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 5.08</td><td align="left">0.121</td><td align="left">&#x02009;&#x02212; 11.50</td><td align="left">1.33</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Alcoholism or alcohol problem</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 3.68</td><td align="left">0.178</td><td align="left">&#x02009;&#x02212; 9.04</td><td align="left">1.67</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Drug problems</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">15.10</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">7.64</td><td align="left">22.55</td><td align="left">&#x02009;&#x02212; 10.23</td><td align="left">0.001</td><td align="left">&#x02009;&#x02212; 16.47</td><td align="left">&#x02009;&#x02212; 4.00</td></tr><tr><td align="left">Significant interactions</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x003b2;_int</td><td align="left"><italic>P</italic></td><td align="left" colspan="2">95% CI</td></tr><tr><td align="left" colspan="13">With mental health</td></tr><tr><td align="left">ADT</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 4.27</td><td align="left">0.003</td><td align="left">&#x02009;&#x02212; 7.11</td><td align="left">&#x02009;&#x02212; 1.42</td></tr><tr><td align="left" colspan="13">With bowel</td></tr><tr><td align="left">Watchful waiting</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 4.04</td><td align="left">0.008</td><td align="left">&#x02009;&#x02212; 7.04</td><td align="left">1.05</td></tr><tr><td align="left">ADT</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 2.80</td><td align="left">0.047</td><td align="left">&#x02009;&#x02212; 5.67</td><td align="left">&#x02212;0.08</td></tr></tbody></table></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Hierarchical regression models for QoL and supportive care needs (M&#x00101;ori)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Overall supportive care needs (M&#x00101;ori)</th><th align="left" colspan="4">Basic model</th><th align="left" colspan="4">Adjusted model</th><th align="left" colspan="4">Interaction model</th></tr><tr><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left">95% CI</th><th align="left"/><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left">95% CI</th><th align="left"/><th align="left"><italic>&#x003b2;</italic></th><th align="left"><italic>P</italic></th><th align="left">95% CI</th><th align="left"/></tr></thead><tbody><tr><td align="left">Physical health</td><td align="left">&#x02009;&#x02212; 2.21</td><td align="left">0.121</td><td align="left">&#x02009;&#x02212; 5.00</td><td align="left">0.59</td><td align="left">&#x02009;&#x02212; 4.23</td><td align="left">0.014</td><td align="left">&#x02009;&#x02212; 7.59</td><td align="left">&#x02009;&#x02212; 0.87</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Mental health</td><td align="left">&#x02009;&#x02212; 8.50</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 11.37</td><td align="left">&#x02009;&#x02212; 5.63</td><td align="left">&#x02009;&#x02212; 5.09</td><td align="left">0.003</td><td align="left">&#x02009;&#x02212; 8.38</td><td align="left">&#x02009;&#x02212; 1.80</td><td align="left">&#x02009;&#x02212; 6.30</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 9.21</td><td align="left">&#x02009;&#x02212; 3.40</td></tr><tr><td align="left">Urinary incontinence</td><td align="left">&#x02009;&#x02212; 3.07</td><td align="left">0.057</td><td align="left">&#x02009;&#x02212; 6.24</td><td align="left">0.10</td><td align="left">&#x02009;&#x02212; 5.53</td><td align="left">0.001</td><td align="left">&#x02009;&#x02212; 8.80</td><td align="left">&#x02009;&#x02212; 2.26</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Urinary obstructive</td><td align="left">&#x02009;&#x02212; 4.60</td><td align="left">0.006</td><td align="left">&#x02009;&#x02212; 7.83</td><td align="left">&#x02009;&#x02212; 1.36</td><td align="left">&#x02009;&#x02212; 0.22</td><td align="left">0.907</td><td align="left">&#x02009;&#x02212; 3.97</td><td align="left">3.53</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Bowel</td><td align="left">&#x02009;&#x02212; 4.11</td><td align="left">0.007</td><td align="left">&#x02009;&#x02212; 7.08</td><td align="left">&#x02009;&#x02212; 1.15</td><td align="left">&#x02009;&#x02212; 0.04</td><td align="left">0.985</td><td align="left">&#x02009;&#x02212; 3.62</td><td align="left">3.55</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Sexual</td><td align="left">0.63</td><td align="left">0.719</td><td align="left">&#x02009;&#x02212; 2.84</td><td align="left">4.10</td><td align="left">0.22</td><td align="left">0.886</td><td align="left">&#x02009;&#x02212; 2.79</td><td align="left">3.22</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Hormonal</td><td align="left">&#x02009;&#x02212; 4.68</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 7.35</td><td align="left">&#x02009;&#x02212; 2.12</td><td align="left">&#x02009;&#x02212; 8.69</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 11.75</td><td align="left">&#x02009;&#x02212; 5.63</td><td align="left">&#x02009;&#x02212; 8.21</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">&#x02009;&#x02212; 10.76</td><td align="left">&#x02009;&#x02212; 5.66</td></tr><tr><td align="left" colspan="13">Relationship (vs living with spouse)</td></tr><tr><td align="left">In a relationship, not living together</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">11.12</td><td align="left">0.145</td><td align="left">&#x02009;&#x02212; 3.92</td><td align="left">26.15</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Not in a relationship</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">13.11</td><td align="left">0.066</td><td align="left">&#x02009;&#x02212; 0.87</td><td align="left">27.10</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Marital status (vs never married)</td></tr><tr><td align="left">Married</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 8.99</td><td align="left">0.621</td><td align="left">&#x02009;&#x02212; 5.55</td><td align="left">32.44</td><td align="left">2.31</td><td align="left">0.072</td><td align="left">&#x02009;&#x02212; 0.21</td><td align="left">4.83</td></tr><tr><td align="left">Separated</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">6.66</td><td align="left">0.386</td><td align="left">&#x02009;&#x02212; 8.54</td><td align="left">21.86</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Divorced</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">17.35</td><td align="left">0.004</td><td align="left">5.60</td><td align="left">29.10</td><td align="left">5.94</td><td align="left">0.048</td><td align="left">0.04</td><td align="left">11.84</td></tr><tr><td align="left">Widower</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">8.90</td><td align="left">0.172</td><td align="left">&#x02009;&#x02212; 3.96</td><td align="left">21.77</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Employment (vs full-time)</td></tr><tr><td align="left">Part-time</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 10.67</td><td align="left">0.026</td><td align="left">&#x02009;&#x02212; 20.01</td><td align="left">&#x02009;&#x02212; 1.33</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Seeking opportunities</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">17.66</td><td align="left">0.072</td><td align="left">&#x02009;&#x02212; 1.60</td><td align="left">36.93</td><td align="left">13.95</td><td align="left">0.019</td><td align="left">2.31</td><td align="left">25.58</td></tr><tr><td align="left">Retired</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 3.68</td><td align="left">0.404</td><td align="left">&#x02009;&#x02212; 12.41</td><td align="left">5.05</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Prefer not to say</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">5.05</td><td align="left">0.773</td><td align="left">&#x02009;&#x02212; 29.72</td><td align="left">39.83</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Smoke status (vs non-smoker)</td></tr><tr><td align="left">Smoke</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">22.27</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">12.35</td><td align="left">32.19</td><td align="left">18.13</td><td align="left">&#x02009;&#x0003c; 0.001</td><td align="left">23.48</td><td align="left">12.77</td></tr><tr><td align="left" colspan="13">Education (vs below high school level)</td></tr><tr><td align="left">High school level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">6.17</td><td align="left">0.293</td><td align="left">&#x02009;&#x02212; 5.42</td><td align="left">17.75</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">University level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">12.78</td><td align="left">0.062</td><td align="left">&#x02009;&#x02212; 0.67</td><td align="left">26.22</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Postgraduate level</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">13.58</td><td align="left">0.059</td><td align="left">&#x02009;&#x02212; 0.55</td><td align="left">27.72</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Prefer not to say</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 10.24</td><td align="left">0.290</td><td align="left">&#x02009;&#x02212; 29.39</td><td align="left">8.90</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Household income (vs below 100 k)</td></tr><tr><td align="left">More than 100 k</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 5.27</td><td align="left">0.245</td><td align="left">&#x02009;&#x02212; 14.22</td><td align="left">3.68</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="13">Medical conditions (vs no conditions)</td></tr><tr><td align="left">Diabetes</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 2.87</td><td align="left">0.520</td><td align="left">&#x02009;&#x02212; 11.72</td><td align="left">5.98</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Heart attack, chest pain</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">6.35</td><td align="left">0.102</td><td align="left">&#x02009;&#x02212; 1.29</td><td align="left">13.99</td><td align="left">8.39</td><td align="left">0.003</td><td align="left">13.93</td><td align="left">2.85</td></tr><tr><td align="left">Stroke</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 1.39</td><td align="left">0.765</td><td align="left">&#x02009;&#x02212; 10.63</td><td align="left">7.84</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Amputation</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">20.75</td><td align="left">0.005</td><td align="left">6.53</td><td align="left">34.97</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Circulation problems</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.96</td><td align="left">0.478</td><td align="left">&#x02009;&#x02212; 5.30</td><td align="left">11.22</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Asthma or emphysema</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.84</td><td align="left">0.864</td><td align="left">&#x02009;&#x02212; 10.54</td><td align="left">8.86</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Stomach ulcer, irritable bowel</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 7.37</td><td align="left">0.114</td><td align="left">&#x02009;&#x02212; 16.54</td><td align="left">1.80</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Kidney disease</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 0.85</td><td align="left">0.859</td><td align="left">&#x02009;&#x02212; 10.27</td><td align="left">8.58</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Major depression</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 2.89</td><td align="left">0.633</td><td align="left">&#x02009;&#x02212; 14.88</td><td align="left">9.10</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Seizures</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">omitted</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Alcoholism or alcohol problem</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">7.21</td><td align="left">0.196</td><td align="left">&#x02009;&#x02212; 3.79</td><td align="left">18.20</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Drug problems</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x02009;&#x02212; 1.38</td><td align="left">0.824</td><td align="left">&#x02009;&#x02212; 13.68</td><td align="left">10.92</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Significant interactions</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x003b2;_int</td><td align="left"><italic>P</italic></td><td align="left" colspan="2">95% CI</td></tr><tr><td align="left" colspan="13">With physical health</td></tr><tr><td align="left">&#x000a0; Service utilization</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.29</td><td align="left">0.046</td><td align="left">0.01</td><td align="left">0.58</td></tr><tr><td align="left" colspan="13">With mental health</td></tr><tr><td align="left">&#x000a0; Radical prostatectomy</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">6.36</td><td align="left">0.002</td><td align="left">2.32</td><td align="left">10.41</td></tr><tr><td align="left">&#x000a0; Service utilization</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.14</td><td align="left">0.033</td><td align="left">0.01</td><td align="left">0.26</td></tr><tr><td align="left" colspan="13">With hormonal</td></tr><tr><td align="left">&#x000a0; Radical prostatectomy</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.69</td><td align="left">0.028</td><td align="left">1.12</td><td align="left">7.52</td></tr></tbody></table><table-wrap-foot><p>LASSO inference was applied in the interaction model to effectively address high collinearity and perform variable selection. Only the variables selected by LASSO were included in the interaction model</p><p>To ensure that the interaction effects are built upon robust main effects, significant interactions are presented where the corresponding relationships in the adjusted model were also significant</p></table-wrap-foot></table-wrap></p><p id="Par29">For M&#x00101;ori PCS, poorer mental health (<italic>&#x003b2;</italic>&#x02009;= &#x02013;8.50, <italic>p</italic>&#x02009;&#x0003c; 0.001) and more severe hormonal symptoms (<italic>&#x003b2;</italic>&#x02009;= &#x02013;4.68, <italic>p</italic>&#x02009;&#x0003c; 0.001) were significantly associated with higher SCN in the basic model, alongside urinary obstructive and bowel issues. In the adjusted model for M&#x00101;ori, mental health (<italic>&#x003b2;</italic>&#x02009;= &#x02013;5.09, <italic>p</italic>&#x02009;= 0.003) and hormonal issues (<italic>&#x003b2;</italic>&#x02009;= &#x02013;8.69, <italic>p</italic>&#x02009;&#x0003c; 0.001) remained significant, and physical health emerged as a significant predictor of SCN (<italic>&#x003b2;</italic>&#x02009;= &#x02013;4.23, <italic>p</italic>&#x02009;= 0.014). In the interaction model for M&#x00101;ori, greater utilization of supportive care services buffered some of the negative effects of poor QoL on SCN: the association of poor physical health with SCN was slightly reduced with higher service use (&#x003b2;_interaction =&#x02009;0.29, <italic>p</italic>&#x02009;= 0.046), as was the association of poor mental health with SCN (&#x003b2;_interaction =&#x02009;0.14, <italic>p</italic>&#x02009;= 0.033). Moreover, having undergone RP mitigated some of the needs associated with poor mental health (&#x003b2;_interaction =&#x02009;6.36, <italic>p</italic>&#x02009;= 0.002) and hormonal issues (&#x003b2;_interaction =&#x02009;3.69, p&#x02009;= 0.028) in M&#x00101;ori patients.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par30">This study examined the associations between QoL and SCN in PCS, highlighting significant disparities between M&#x00101;ori and non-M&#x00101;ori patients in NZ. Most QoL domains were negatively associated with SCN, particularly mental health and hormonal issues remaining significant in both groups. Our findings also reveal several important insights into how different treatment modalities and the utilization of care services interact with QoL domains to influence SCN. It is shown that ADT and watchful waiting appeared to exacerbate some of the negative effects, whereas the RP and use of the care services in M&#x00101;ori groups may mitigate these effects.</p><p id="Par31">M&#x00101;ori men demonstrated markedly lower scores in both the physical, and mental health scores, aligning with known disparities linked to social characteristics, biological differences, variations in treatment received, and disparities in access to or utilization of supportive care services [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. For instance, our data reveal that M&#x00101;ori men are more likely to have below high school-level education, live alone or be in non-cohabiting relationships, and report lower household incomes. These align with earlier studies, which emphasize how socioeconomic disadvantages and social isolation contribute to poorer mental health outcomes and lower QoL in M&#x00101;ori [<xref ref-type="bibr" rid="CR20">20</xref>]. Notably, our adjusted model shows that physical health significantly affects SCN among M&#x00101;ori patients, whereas it remains insignificant for non-M&#x00101;ori patients. This discrepancy may be due to the higher prevalence of comorbidities among M&#x00101;ori PCS, which increase the physical health burden [<xref ref-type="bibr" rid="CR12">12</xref>]. Interestingly, after incorporating all the treatment interaction terms, the relationship between physical health and SCN becomes significant for non-M&#x00101;ori patients in the interaction model. This suggests that the impact of treatments on SCN is also substantial for non-M&#x00101;ori patients. There are consistent themes regarding the influence of mental health and hormonal issues on SCN. Earlier research highlighted that PCS with psychological distress had greater unmet SCN across all domains [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Our study corroborates these findings, demonstrating that poor mental health significantly increases SCN. Moreover, hormonal issues also emerged as a critical factor in both groups, aligning with findings highlighting the profound impact of treatment-related hormonal changes on QoL [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par32">Our results indicate that treatment modalities significantly influence SCN. M&#x00101;ori men exhibited higher rates of watchful waiting, ADT, and hormonal therapy but fewer radical prostatectomies compared to non-M&#x00101;ori, consistent with previous research in NZ [<xref ref-type="bibr" rid="CR23">23</xref>]. The previous study also shows that RP is associated with an increased risk of urinary incontinence, and ADT is associated with erectile dysfunction and urinary incontinence [<xref ref-type="bibr" rid="CR24">24</xref>]. ADT notably exacerbated negative associations between mental health, bowel function, and SCN, possibly due to hormonal disruptions increased rates of anxiety and depression, as well as the incidence of inflammatory bowel disease among PCS [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Symptoms such as fatigue, loss of muscle mass, cognitive decline, and sexual dysfunction further contribute to overall psychological distress [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. This added burden can worsen the mental health of patients, thereby increasing their SCN.</p><p id="Par33">For bowel issues, the exacerbation may result from ADT negatively altering gut microbiota and gastrointestinal function [<xref ref-type="bibr" rid="CR31">31</xref>]. Watchful waiting as a treatment involves monitoring the cancer without active intervention until symptoms worsen. This can lead to a deterioration in bowel function over time and an increase in SCN. Our interaction analysis revealed that watchful waiting significantly strengthened the negative association between bowel function and SCN among non-M&#x00101;ori PCS. While previous studies typically linked bowel dysfunction to active treatments like surgery or radiotherapy [<xref ref-type="bibr" rid="CR32">32</xref>]. Our results suggest that watchful waiting, while less invasive, may still contribute to bowel-related challenges. This may reflect disease progression, delayed symptom management, or prolonged uncertainty and anxiety, potentially exacerbating psychological distress, creating a cycle of increasing SCN. In contrast, RP appear to mitigate these negative associations of SCN with mental health and hormonal issues for M&#x00101;ori patients. It is possibly due to the definitive nature of surgery, providing immediate cancer removal and reducing psychological distress associated with disease management. While M&#x00101;ori men in our study were more likely to receive less invasive treatments, those who underwent RP experienced notable benefits in mitigating SCN. However, the role of RP in older men with low-risk prostate cancer remains uncertain, as previous studies have found no significant survival benefit in this population [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Conversely, RP has shown benefits for patients with intermediate- and high-risk disease, potentially preventing metastatic seeding of cancer cells and improving disease control [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par34">It is also important to recognize that &#x0201c;treatment received&#x0201d; does not always equate to &#x0201c;treatment preference&#x0201d;. In many cases, systemic barriers and healthcare access constraints frequently influence treatment decisions, especially among M&#x00101;ori men [<xref ref-type="bibr" rid="CR3">3</xref>]. This context is crucial when interpreting the apparent benefits of RP on SCN: while some patients clearly benefit from surgical intervention, not all have equal access to this option. Recognizing these nuances underscores the importance of care service utilization in further mitigating SCN. Our interaction model reveals that supportive care service utilization significantly reduces SCN related to physical and mental health among M&#x00101;ori patients. Although the interaction coefficients are relatively small, this positive outcome may reflect improvements in the accessibility and cultural sensitivity of care services in NZ. Given that Te Ao M&#x00101;ori emphasizes the interconnectedness between people, community, and environment, culturally sensitive healthcare services are crucial in shaping how health and care services are perceived and utilized by M&#x00101;ori [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. This is also reflected in our demographic data where proportionally more M&#x00101;ori patients receive non-invasive or minimally invasive treatments than NZ European patients, but fewer M&#x00101;ori men are using care services. It is, therefore, crucial to enhance these services to ensure they meet the cultural and health needs of M&#x00101;ori patients effectively.</p><p id="Par35">Finally, our results do not imply the inherent superiority of any treatment modality. Instead, treatment interactions indicate that ADT might increase SCN among those with poor mental health or bowel function but could benefit those with fewer issues. Similarly, RP should be considered thoughtfully, especially for M&#x00101;ori patients with good mental health and fewer hormonal issues, acknowledging that surgery itself can also lead to increased SCN. Patient-centered decision-making and tailored supportive interventions are therefore essential to minimize treatment-related adverse effects.</p><sec id="Sec8"><title>Strength, limitation, and future implications</title><p id="Par36">A key strength of this study is the deliberate oversampling of M&#x00101;ori participants, which increased their representation to 16.9% of the sample (versus ~&#x02009;9.4% in the registry) and improved the reliability of cross-ethnic comparisons. A notable methodological consideration in this study is the use of two versions of the SCN assessment (SCNS-34SF for non-M&#x00101;ori and an adapted SCNAT-IP for M&#x00101;ori), enabling us to capture both general and culturally specific needs. However, this also means that direct comparisons between M&#x00101;ori and non-M&#x00101;ori groups should be interpreted with caution, as differences may reflect both true disparities in unmet needs and measurement variances arising from the distinct survey instruments. Despite this oversampling, the relatively small sample size of M&#x00101;ori PCS still presented challenges for the analysis. This constrained sample size necessitated the removal of some high collinearity variables to maintain the robustness and interpretability of the statistical models, consequently reducing the statistical power of the interaction analyses. Additionally, while the study adjusted for various demographic and clinical factors, there might be unmeasured confounding variables influencing the outcomes, such as residential locations affecting access to healthcare. The limited representation of specific minority groups, such as S&#x00101;moan and Niuean PCS, required their inclusion in the broader non-M&#x00101;ori group, potentially obscuring their unique SCN. One other significant limitation is the cross-sectional design, which restricts the ability to infer causality between the variables studied.</p><p id="Par37">Despite these limitations, the findings from this study have important implications for future research and clinical practice. The significant disparities in SCN and QoL between M&#x00101;ori and non-M&#x00101;ori PCS underscore the necessity for culturally tailored supportive care interventions. Incorporating principles from Te Ao M&#x00101;ori into care services could ensure culturally relevant and holistic care, potentially mitigating the inequities observed [<xref ref-type="bibr" rid="CR38">38</xref>]. Future research should focus on these identified interacting treatments and apply advanced analytical techniques, such as Latent Profile Analysis [<xref ref-type="bibr" rid="CR39">39</xref>], to identify distinct subgroups of patients with similar SCN. Longitudinal studies following patients over time (before, during, and after treatment) are warranted to see how QoL and SCN evolve throughout the cancer journey. Such research would provide deeper insights into the timing and impact of different treatments on QoL and needs, and would help in designing more effective, personalized supportive care strategies for PCS.</p></sec></sec><sec id="Sec9"><title>Conclusion</title><p id="Par38">This study explored the complex associations between QoL and SCN among PCS in NZ, highlighting significant disparities between M&#x00101;ori and non-M&#x00101;ori patients. We found negative associations between most QoL domains and SCN, especially concerning mental health and hormonal issues. Our study is the first in NZ to explore the interaction effects of different treatments on SCN and QoL. Among these, ADT can exacerbate some negative effects, while care service use might mitigate physical and mental health impacts for M&#x00101;ori. These findings highlight the need for tailored supportive care services, improving treatment choices, and clinical outcomes, and reducing healthcare disparities, particularly for underrepresented groups like M&#x00101;ori men.</p></sec><sec id="Sec10" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="520_2025_9521_MOESM1_ESM.docx"><caption><p>Supplementary Material 1 (DOCX 37.7 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="520_2025_9521_MOESM2_ESM.pdf"><caption><p>Supplementary Material 2 (PDF 904 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions
</title><p>All authors contributed to the study's conception and design. The first draft of the manuscript was written by Hui Xiao and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The University of Otago. This work was supported by Strategy Development Grant, Department of Anatomy, University of Otago and Lottery Health Research Grant NZ.</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interest
</title><p id="Par39">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Matti</surname><given-names>B</given-names></name><name><surname>Zargar-Shoshtari</surname><given-names>K</given-names></name></person-group><article-title>Prostate cancer outcomes disparities: population survival analysis in an ethnically diverse nation</article-title><source>Urol Oncol: Semin Original Inv</source><year>2021</year><volume>39</volume><issue>6</issue><fpage>367.e19</fpage><lpage>367.e26</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2021.02.023</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Matti B, Zargar-Shoshtari K (2021) Prostate cancer outcomes disparities: population survival analysis in an ethnically diverse nation. Urol Oncol: Seminars Original Investigations 39(6):367.e19-367.e26</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Wibowo</surname><given-names>E</given-names></name><name><surname>Schellhammer</surname><given-names>PF</given-names></name><name><surname>Montie</surname><given-names>JE</given-names></name><name><surname>Lange</surname><given-names>PH</given-names></name><name><surname>Goldenberg</surname><given-names>SL</given-names></name><name><surname>Wassersug</surname><given-names>RJ</given-names></name></person-group><article-title>&#x02018;Should I get a PSA test?&#x02019; &#x02013; the question is not that simple</article-title><source>Trends Urol Men's Health</source><year>2015</year><volume>6</volume><fpage>31</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/tre.484</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Wibowo E, Schellhammer PF, Montie JE, Lange PH, Goldenberg SL, Wassersug RJ (2015) &#x02018;Should I get a PSA test?&#x02019; &#x02013; the question is not that simple. Trends in Urology &#x00026; Men&#x02019;s Health 6:31&#x02013;34</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>R</given-names></name><name><surname>Lawrenson</surname><given-names>R</given-names></name><name><surname>Kidd</surname><given-names>J</given-names></name><name><surname>Cassim</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Blundell</surname><given-names>R</given-names></name><name><surname>Bateman</surname><given-names>J</given-names></name><name><surname>Broughton</surname><given-names>JR</given-names></name></person-group><article-title>Inequalities between M&#x00101;ori and non-M&#x00101;ori men with prostate cancer in Aotearoa New Zealand</article-title><source>NZ Med J</source><year>2020</year><volume>133</volume><issue>1521</issue><fpage>69</fpage><lpage>76</lpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Egan R, Lawrenson R, Kidd J, Cassim S, Black S, Blundell R, Bateman J, Broughton JR (2020) Inequalities between M&#x00101;ori and non-M&#x00101;ori men with prostate cancer in Aotearoa New Zealand. NZ Med J 133(1521):69&#x02013;76</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Baxter</surname><given-names>GD</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Hoeta</surname><given-names>T</given-names></name><name><surname>Wibowo</surname><given-names>E</given-names></name></person-group><article-title>The landscape of supportive care needs among prostate cancer patients in New Zealand: a cross-ethnic analysis</article-title><source>Psychooncology</source><year>2025</year><volume>34</volume><issue>2</issue><fpage>e70110</fpage><pub-id pub-id-type="doi">10.1002/pon.70110</pub-id><pub-id pub-id-type="pmid">39984302</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Xiao H, Baxter GD, Liu L, Hoeta T, Wibowo E (2025) The landscape of supportive care needs among prostate cancer patients in New Zealand: a cross-ethnic analysis. Psychooncology 34(2):e70110. 10.1002/pon.70110<pub-id pub-id-type="pmid">39984302</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Korfage</surname><given-names>IJ</given-names></name><name><surname>Hak</surname><given-names>T</given-names></name><name><surname>de Koning</surname><given-names>HJ</given-names></name><name><surname>Essink-Bot</surname><given-names>M-L</given-names></name></person-group><article-title>Patients&#x02019; perceptions of the side-effects of prostate cancer treatment -a qualitative interview study</article-title><source>Soc Sci Med</source><year>2006</year><volume>63</volume><issue>4</issue><fpage>911</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2006.01.027</pub-id><pub-id pub-id-type="pmid">16798130</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Korfage IJ, Hak T, de Koning HJ, Essink-Bot M-L (2006) Patients&#x02019; perceptions of the side-effects of prostate cancer treatment -a qualitative interview study. Soc Sci Med 63(4):911&#x02013;919<pub-id pub-id-type="pmid">16798130</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>CG</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Testa</surname><given-names>M</given-names></name><name><surname>Kawachi</surname><given-names>I</given-names></name></person-group><article-title>The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer</article-title><source>J Urol</source><year>2001</year><volume>166</volume><issue>5</issue><fpage>1804</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1016/S0022-5347(05)65679-0</pub-id><pub-id pub-id-type="pmid">11586228</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bacon CG, Giovannucci E, Testa M, Kawachi I (2001) The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 166(5):1804&#x02013;1810<pub-id pub-id-type="pmid">11586228</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Prashar</surname><given-names>J</given-names></name><name><surname>Schartau</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>E</given-names></name></person-group><article-title>Supportive care needs of men with prostate cancer: a systematic review update</article-title><source>Eur J Cancer Care</source><year>2022</year><volume>31</volume><issue>2</issue><fpage>e13541</fpage><pub-id pub-id-type="doi">10.1111/ecc.13541</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Prashar J, Schartau P, Murray E (2022) Supportive care needs of men with prostate cancer: a systematic review update. Eur J Cancer Care 31(2):e13541</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Cockle-Hearne</surname><given-names>J</given-names></name><name><surname>Charnay-Sonnek</surname><given-names>F</given-names></name><name><surname>Denis</surname><given-names>L</given-names></name><name><surname>Fairbanks</surname><given-names>H</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Kav</surname><given-names>S</given-names></name><etal/></person-group><article-title>The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><issue>8</issue><fpage>2121</fpage><lpage>2130</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.568</pub-id><pub-id pub-id-type="pmid">24064968</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Cockle-Hearne J, Charnay-Sonnek F, Denis L, Fairbanks H, Kelly D, Kav S et al (2013) The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. Br J Cancer 109(8):2121&#x02013;2130<pub-id pub-id-type="pmid">24064968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Ministry of Health NZ (2018) Evaluation of the cancer psychological and social support initiative: interim reports one and two sapere research group.<ext-link ext-link-type="uri" xlink:href="https://www.health.govt.nz/publication/interim-report-one-and-two-evaluation-cancer-psychological-and-social-support-initiative">https://www.health.govt.nz/publication/interim-report-one-and-two-evaluation-cancer-psychological-and-social-support-initiative</ext-link></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>J</given-names></name><name><surname>Egan</surname><given-names>R</given-names></name><name><surname>Maclennan</surname><given-names>K</given-names></name></person-group><article-title>&#x02018;Survivorship care is one big gap&#x02019;: a qualitative study of post-treatment supportive care in Aotearoa New Zealand</article-title><source>BMC Health Serv Res</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>594</fpage><pub-id pub-id-type="doi">10.1186/s12913-023-09580-8</pub-id><pub-id pub-id-type="pmid">37291526</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bateman J, Egan R, Maclennan K (2023) &#x02018;Survivorship care is one big gap&#x02019;: a qualitative study of post-treatment supportive care in Aotearoa New Zealand. BMC Health Serv Res 23(1):594<pub-id pub-id-type="pmid">37291526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>J</given-names></name><name><surname>Raphael</surname><given-names>D</given-names></name><name><surname>Cassim</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Blundell</surname><given-names>R</given-names></name><name><surname>Egan</surname><given-names>R</given-names></name></person-group><article-title>Health service provider responses to indigenous peoples with cancer: an integrative review</article-title><source>Eur J Cancer Care</source><year>2019</year><volume>28</volume><issue>2</issue><fpage>e12975</fpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kidd J, Raphael D, Cassim S, Black S, Blundell R, Egan R (2019) Health service provider responses to indigenous peoples with cancer: an integrative review. Eur J Cancer Care 28(2):e12975</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Obertov&#x000e1;</surname><given-names>Z</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Lawrenson</surname><given-names>R</given-names></name></person-group><article-title>Survival disparities between M&#x00101;ori and non-M&#x00101;ori men with prostate cancer in New Zealand</article-title><source>Br J Urol</source><year>2015</year><volume>115</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/bju.12900</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Obertov&#x000e1; Z, Scott N, Brown C, Stewart A, Lawrenson R (2015) Survival disparities between M&#x00101;ori and non-M&#x00101;ori men with prostate cancer in New Zealand. Br J Urol 115:24&#x02013;30</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>M</given-names></name><name><surname>Doveson</surname><given-names>S</given-names></name><name><surname>Lindqvist</surname><given-names>O</given-names></name><name><surname>Wennman-Larsen</surname><given-names>A</given-names></name><name><surname>Fransson</surname><given-names>P</given-names></name></person-group><article-title>Quality of life in men with metastatic prostate cancer in their final years before death&#x02013;a retrospective analysis of prospective data</article-title><source>BMC Palliat Care</source><year>2018</year><volume>17</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s12904-018-0381-6</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Holm M, Doveson S, Lindqvist O, Wennman-Larsen A, Fransson P (2018) Quality of life in men with metastatic prostate cancer in their final years before death&#x02013;a retrospective analysis of prospective data. BMC Palliat Care 17:1&#x02013;8</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Centre for Men's Health NZ. Supportive care needs in prostate cancer (SUPPRO) research study 2023 [retrieved 2024 April, cited 2024 May 6]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.otago.ac.nz/mens-health/research/supportive-care-needs-in-prostate-cancer-suppro-research-study">https://www.otago.ac.nz/mens-health/research/supportive-care-needs-in-prostate-cancer-suppro-research-study</ext-link></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Boyes</surname><given-names>A</given-names></name><name><surname>Girgis</surname><given-names>A</given-names></name><name><surname>Lecathelinais</surname><given-names>C</given-names></name></person-group><article-title>Brief assessment of adult cancer patients&#x02019; perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34)</article-title><source>J Eval Clin Pract</source><year>2009</year><volume>15</volume><issue>4</issue><fpage>602</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2753.2008.01057.x</pub-id><pub-id pub-id-type="pmid">19522727</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Boyes A, Girgis A, Lecathelinais C (2009) Brief assessment of adult cancer patients&#x02019; perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). J Eval Clin Pract 15(4):602&#x02013;606. 10.1111/j.1365-2753.2008.01057.x<pub-id pub-id-type="pmid">19522727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Garvey</surname><given-names>G</given-names></name><name><surname>Beesley</surname><given-names>VL</given-names></name><name><surname>Janda</surname><given-names>M</given-names></name><name><surname>Jacka</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>AC</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>P</given-names></name><name><surname>Valery</surname><given-names>PC</given-names></name></person-group><article-title>The development of a supportive care needs assessment tool for Indigenous people with cancer</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-300</pub-id><pub-id pub-id-type="pmid">22212211</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Garvey G, Beesley VL, Janda M, Jacka C, Green AC, O&#x02019;Rourke P, Valery PC (2012) The development of a supportive care needs assessment tool for Indigenous people with cancer. BMC Cancer 12:1<pub-id pub-id-type="pmid">22212211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Einstein</surname><given-names>DJ</given-names></name><name><surname>Patil</surname><given-names>D</given-names></name><name><surname>Chipman</surname><given-names>J</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><name><surname>Crociani</surname><given-names>CM</given-names></name><name><surname>Wagner</surname><given-names>AA</given-names></name><name><surname>Sanda</surname><given-names>MG</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name></person-group><article-title>Expanded Prostate Cancer Index Composite-26 (EPIC-26) online: validation of an internet-based instrument for assessment of health-related quality of life after treatment for localized prostate Cancer</article-title><source>Urology</source><year>2019</year><volume>127</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2019.02.004</pub-id><pub-id pub-id-type="pmid">30790648</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, Wagner AA, Sanda MG, Chang P (2019) Expanded Prostate Cancer Index Composite-26 (EPIC-26) online: validation of an internet-based instrument for assessment of health-related quality of life after treatment for localized prostate Cancer. Urology 127:53&#x02013;60<pub-id pub-id-type="pmid">30790648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>AJL</given-names></name><name><surname>Evans</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>THM</given-names></name><etal/></person-group><article-title>Prostate cancer and supportive care: a systematic review and qualitative synthesis of men&#x02019;s experiences and unmet needs</article-title><source>Eur J Cancer Care (Engl)</source><year>2015</year><volume>24</volume><issue>5</issue><fpage>618</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1111/ecc.12286</pub-id><pub-id pub-id-type="pmid">25630851</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">King AJL, Evans M, Moore THM et al (2015) Prostate cancer and supportive care: a systematic review and qualitative synthesis of men&#x02019;s experiences and unmet needs. Eur J Cancer Care (Engl) 24(5):618&#x02013;634. 10.1111/ecc.12286<pub-id pub-id-type="pmid">25630851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ream</surname><given-names>E</given-names></name><name><surname>Quennell</surname><given-names>A</given-names></name><name><surname>Fincham</surname><given-names>L</given-names></name><name><surname>Faithfull</surname><given-names>S</given-names></name><name><surname>Khoo</surname><given-names>V</given-names></name><name><surname>Wilson-Barnett</surname><given-names>J</given-names></name><etal/></person-group><article-title>Supportive care needs of men living with prostate cancer in England: a survey</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><issue>12</issue><fpage>1903</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604406</pub-id><pub-id pub-id-type="pmid">18506142</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J et al (2008) Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer 98(12):1903&#x02013;1909<pub-id pub-id-type="pmid">18506142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>C</given-names></name><name><surname>Obertov&#x000e1;</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Edlin</surname><given-names>R</given-names></name><name><surname>Gilling</surname><given-names>P</given-names></name><etal/></person-group><article-title>Differences in survival between M&#x00101;ori and New Zealand Europeans with prostate cancer</article-title><source>Eur J Cancer Care</source><year>2016</year><volume>25</volume><issue>2</issue><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1111/ecc.12468</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lao C, Obertov&#x000e1; Z, Brown C, Scott N, Edlin R, Gilling P et al (2016) Differences in survival between M&#x00101;ori and New Zealand Europeans with prostate cancer. Eur J Cancer Care 25(2):262&#x02013;268</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>KM</given-names></name><name><surname>Kelly</surname><given-names>SP</given-names></name><name><surname>Luta</surname><given-names>G</given-names></name><name><surname>Tomko</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Taylor</surname><given-names>KL</given-names></name></person-group><article-title>The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors</article-title><source>Urology</source><year>2014</year><volume>84</volume><issue>2</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2014.04.036</pub-id><pub-id pub-id-type="pmid">24975711</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL (2014) The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology 84(2):300&#x02013;306<pub-id pub-id-type="pmid">24975711</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Galv&#x000e3;o</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><name><surname>Gardiner</surname><given-names>RA</given-names></name><name><surname>Girgis</surname><given-names>A</given-names></name><name><surname>Lepore</surname><given-names>SJ</given-names></name><name><surname>Stiller</surname><given-names>A</given-names></name><etal/></person-group><article-title>Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life</article-title><source>Psychooncology</source><year>2015</year><volume>24</volume><issue>10</issue><fpage>1241</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1002/pon.3882</pub-id><pub-id pub-id-type="pmid">26087455</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Galv&#x000e3;o DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A et al (2015) Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psychooncology 24(10):1241&#x02013;1249<pub-id pub-id-type="pmid">26087455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Korfage IJ, Essink-Bot ML, Janssens AC, Schr&#x000f6;der FH, De Koning HJ (2006) Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer 94(8):1093&#x02013;8</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Obertov&#x000e1;</surname><given-names>Z</given-names></name><name><surname>Lawrenson</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><etal/></person-group><article-title>Treatment modalities for M&#x00101;ori and New Zealand European men with localised prostate cancer</article-title><source>Int J Clin Oncol</source><year>2015</year><volume>20</volume><fpage>814</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s10147-014-0781-4</pub-id><pub-id pub-id-type="pmid">25557325</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Obertov&#x000e1; Z, Lawrenson R, Scott N et al (2015) Treatment modalities for M&#x00101;ori and New Zealand European men with localised prostate cancer. Int J Clin Oncol 20:814&#x02013;820. 10.1007/s10147-014-0781-4<pub-id pub-id-type="pmid">25557325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>S</given-names></name><name><surname>Drevin</surname><given-names>L</given-names></name><name><surname>Loeb</surname><given-names>S</given-names></name><name><surname>Widmark</surname><given-names>A</given-names></name><name><surname>Lissbrant</surname><given-names>IF</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Population-based study of long-term functional outcomes after prostate cancer treatment</article-title><source>BJU Int</source><year>2016</year><volume>117</volume><issue>6B</issue><fpage>E36</fpage><lpage>E45</lpage><pub-id pub-id-type="doi">10.1111/bju.13179</pub-id><pub-id pub-id-type="pmid">25959859</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D et al (2016) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int 117(6B):E36&#x02013;E45<pub-id pub-id-type="pmid">25959859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>PS</given-names></name><name><surname>Govani</surname><given-names>S</given-names></name><name><surname>Borza</surname><given-names>T</given-names></name><name><surname>Hollenbeck</surname><given-names>BK</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Shumway</surname><given-names>D</given-names></name><etal/></person-group><article-title>Implications of prostate cancer treatment in men with inflammatory bowel disease</article-title><source>Urology</source><year>2017</year><volume>104</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2017.01.030</pub-id><pub-id pub-id-type="pmid">28163082</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kirk PS, Govani S, Borza T, Hollenbeck BK, Davis J, Shumway D et al (2017) Implications of prostate cancer treatment in men with inflammatory bowel disease. Urology 104:131&#x02013;136<pub-id pub-id-type="pmid">28163082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>KT</given-names></name><name><surname>Reznor</surname><given-names>G</given-names></name><name><surname>Muralidhar</surname><given-names>V</given-names></name><name><surname>Mahal</surname><given-names>BA</given-names></name><name><surname>Nezolosky</surname><given-names>MD</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Association of androgen deprivation therapy with depression in localized prostate cancer</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>16</issue><fpage>1905</fpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.1969</pub-id><pub-id pub-id-type="pmid">27069075</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK et al (2016) Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol 34(16):1905<pub-id pub-id-type="pmid">27069075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>KT</given-names></name><name><surname>Yang</surname><given-names>DD</given-names></name><name><surname>Nead</surname><given-names>KT</given-names></name><name><surname>Reznor</surname><given-names>G</given-names></name><name><surname>Trinh</surname><given-names>QD</given-names></name><name><surname>Nguyen</surname><given-names>PL</given-names></name></person-group><article-title>Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer</article-title><source>Int J Urol</source><year>2017</year><volume>24</volume><issue>10</issue><fpage>743</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1111/iju.13409</pub-id><pub-id pub-id-type="pmid">28734019</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dinh KT, Yang DD, Nead KT, Reznor G, Trinh QD, Nguyen PL (2017) Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. Int J Urol 24(10):743&#x02013;748<pub-id pub-id-type="pmid">28734019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Klil-Drori</surname><given-names>AJ</given-names></name><name><surname>Tascilar</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Aprikian</surname><given-names>A</given-names></name><name><surname>Bitton</surname><given-names>A</given-names></name><name><surname>Azoulay</surname><given-names>L</given-names></name></person-group><article-title>Androgen deprivation therapy and the incidence of inflammatory bowel disease in patients with prostate cancer</article-title><source>Am J Epidemiol</source><year>2016</year><volume>184</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/aje/kwv307</pub-id><pub-id pub-id-type="pmid">27268031</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Klil-Drori AJ, Tascilar K, Yin H, Aprikian A, Bitton A, Azoulay L (2016) Androgen deprivation therapy and the incidence of inflammatory bowel disease in patients with prostate cancer. Am J Epidemiol 184(1):15&#x02013;22<pub-id pub-id-type="pmid">27268031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wibowo</surname><given-names>E</given-names></name></person-group><article-title>Cognitive impacts of estrogen treatment in androgen-deprived males: what needs to be resolved</article-title><source>Curr Neuropharmacol</source><year>2017</year><volume>15</volume><issue>7</issue><fpage>1043</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.2174/1570159X15666170313122555</pub-id><pub-id pub-id-type="pmid">28294068</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wibowo E (2017) Cognitive impacts of estrogen treatment in androgen-deprived males: what needs to be resolved. Curr Neuropharmacol 15(7):1043&#x02013;1055<pub-id pub-id-type="pmid">28294068</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Lairson</surname><given-names>DR</given-names></name><name><surname>Swartz</surname><given-names>MD</given-names></name><name><surname>Du</surname><given-names>XL</given-names></name></person-group><article-title>Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer</article-title><source>Pharmacother J Hum Pharmacol Drug Ther</source><year>2018</year><volume>38</volume><issue>10</issue><fpage>999</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1002/phar.2168</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nguyen C, Lairson DR, Swartz MD, Du XL (2018) Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38(10):999&#x02013;1009</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kure</surname><given-names>A</given-names></name><name><surname>Tsukimi</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>C</given-names></name><name><surname>Aw</surname><given-names>W</given-names></name><name><surname>Obana</surname><given-names>N</given-names></name><name><surname>Nakato</surname><given-names>G</given-names></name><etal/></person-group><article-title>Gut environment changes due to androgen deprivation therapy in patients with prostate cancer</article-title><source>Prostate Cancer Prostatic Dis</source><year>2023</year><volume>26</volume><issue>2</issue><fpage>323</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41391-022-00536-3</pub-id><pub-id pub-id-type="pmid">35418210</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kure A, Tsukimi T, Ishii C, Aw W, Obana N, Nakato G et al (2023) Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. Prostate Cancer Prostatic Dis 26(2):323&#x02013;330<pub-id pub-id-type="pmid">35418210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>SJ</given-names></name><name><surname>Calopedos</surname><given-names>RJ</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>DL</given-names></name><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Woo</surname><given-names>HH</given-names></name><name><surname>Smith</surname><given-names>DP</given-names></name></person-group><article-title>Long-term psychological and quality-of-life effects of active surveillance and watchful waiting after diagnosis of low-risk localised prostate cancer</article-title><source>Eur Urol</source><year>2018</year><volume>73</volume><issue>6</issue><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2017.08.013</pub-id><pub-id pub-id-type="pmid">28851582</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Egger SJ, Calopedos RJ, O&#x02019;Connell DL, Chambers SK, Woo HH, Smith DP (2018) Long-term psychological and quality-of-life effects of active surveillance and watchful waiting after diagnosis of low-risk localised prostate cancer. Eur Urol 73(6):859&#x02013;867<pub-id pub-id-type="pmid">28851582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Axelson</surname><given-names>A</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Ruutu</surname><given-names>M</given-names></name><name><surname>H&#x000e4;ggman</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>SO</given-names></name><name><surname>Bratell</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radical prostatectomy versus watchful waiting in early prostate cancer</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>18</issue><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1011967</pub-id><pub-id pub-id-type="pmid">21542742</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Axelson A, Holmberg L, Ruutu M, H&#x000e4;ggman M, Andersson SO, Bratell S et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708&#x02013;1717. 10.1056/NEJMoa1011967<pub-id pub-id-type="pmid">21542742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilt</surname><given-names>TJ</given-names></name><name><surname>Brawer</surname><given-names>MK</given-names></name><name><surname>Jones</surname><given-names>KM</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Aronson</surname><given-names>WJ</given-names></name><name><surname>Fox</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radical prostatectomy versus observation for localized prostate cancer</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>3</issue><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113162</pub-id><pub-id pub-id-type="pmid">22808955</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203&#x02013;213. 10.1056/NEJMoa1113162<pub-id pub-id-type="pmid">22808955</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF (2017) Role of radical prostatectomy in metastatic prostate cancer: a review. Urol Oncol Semin Orig Investig 35(4):125&#x02013;134. Elsevier</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Oakley Browne</surname><given-names>MA</given-names></name></person-group><article-title>Usefulness of the construct of social network to explain mental health service utilization by the M&#x00101;ori population in New Zealand</article-title><source>Transcult Psychiatry</source><year>2008</year><volume>45</volume><issue>3</issue><fpage>439</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1177/1363461508094675</pub-id><pub-id pub-id-type="pmid">18799642</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kumar S, Oakley Browne MA (2008) Usefulness of the construct of social network to explain mental health service utilization by the M&#x00101;ori population in New Zealand. Transcult Psychiatry 45(3):439&#x02013;454<pub-id pub-id-type="pmid">18799642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Ministry of Health NZ (2018) Principles from Te Ao M&#x00101;ori &#x02013; The M&#x00101;ori Worldview | He Aronga M&#x00101;ori ki ng&#x00101; M&#x00101;t&#x00101;pono. <ext-link ext-link-type="uri" xlink:href="https://www.mbie.govt.nz/business-and-employment/economic-development/just-transition/just-transitions-guide/foundations/principles-from-te-ao-maori-the-maori-worldview/">https://www.mbie.govt.nz/business-and-employment/economic-development/just-transition/just-transitions-guide/foundations/principles-from-te-ao-maori-the-maori-worldview/</ext-link></mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Kongsted</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>AM</given-names></name></person-group><article-title>Latent class analysis in health research</article-title><source>J Physiother</source><year>2017</year><volume>63</volume><issue>1</issue><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.jphys.2016.05.018</pub-id><pub-id pub-id-type="pmid">27914733</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kongsted A, Nielsen AM (2017) Latent class analysis in health research. J Physiother 63(1):55&#x02013;58<pub-id pub-id-type="pmid">27914733</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>